第一部分：PK/PD探索研究 1)评价甲磺酸雷沙吉兰透皮贴剂给药一周（4天/贴+3天/贴）的安全性。 2)评价甲磺酸雷沙吉兰透皮贴剂给药一周（4天/贴+3天/贴）的药代动力学和药效动力学特征。 3)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片的药代动力学和药效动力学特征。 4)评价甲磺酸雷沙吉兰透皮贴剂给药后的黏附性、刺激性和致敏性。第二部分：多次给药生物利用度研究 1)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片在健康人体内连续给药的相对生物利用度。 2)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片多次给药的药效动力学特征。 3)评价甲磺酸雷沙吉兰透皮贴剂和甲磺酸雷沙吉兰片多次给药的安全性。 4)评价甲磺酸雷沙吉兰透皮贴剂多次给药的黏附性、刺激性和致敏性。第三部分：不同部位生物利用度研究 1)比较甲磺酸雷沙吉兰透皮贴剂不同部位给药的生物利用度。 2)评价甲磺酸雷沙吉兰透皮贴剂的安全性、黏附性、刺激性和致敏性。

开始日期2025-02-05

申办/合作机构

上海世领制药有限公司

[+1]

CTR20243770

/ CompletedN/A

甲磺酸雷沙吉兰片在健康受试者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、四周期完全重复交叉设计生物等效性试验

研究空腹与餐后状态下单次口服受试制剂（甲磺酸雷沙吉兰片，规格1mg，浙江九洲生物医药有限公司持证）与参比制剂（甲磺酸雷沙吉兰片，规格1mg，商品名安齐来，Teva Pharmaceutical Industries Ltd.持证）在健康受试者体内的药代动力学特征，比较受试制剂与参比制剂的生物等效性，并研究药物在健康受试者体内的安全性。

开始日期2024-11-05

申办/合作机构

浙江九洲生物医药有限公司

CTIS2024-512311-41-00

/ Not yet recruiting临床1期

- UECHUP-RAS/24-2

开始日期2024-06-04

申办/合作机构-

100 项与甲磺酸雷沙吉兰相关的临床结果

登录后查看更多信息

100 项与甲磺酸雷沙吉兰相关的转化医学

登录后查看更多信息

100 项与甲磺酸雷沙吉兰相关的专利（医药）

登录后查看更多信息

1,060

项与甲磺酸雷沙吉兰相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy

Review

作者: Udi, Onoriode Andrew ; Ogbutor, Udoji Godsday ; Atere, Adedeji David ; Oyovwi, Mega Obukohwo ; Joseph, Gregory Uchechukwu

Neurodegenerative diseases like Parkinson's and Alzheimer's are a global health challenge due to their progressive degeneration, leading to cognitive decline and motor dysfunction. Monoamine oxidase B (MAO-B) enzyme is implicated in neurodegeneration, and developing inhibitors could be a promising therapeutic strategy. This review explores MAO-B activity molecular pathways, evaluates MAO-B inhibitors in neurodegenerative therapy, identifies challenges, and suggests future research directions. This review synthesizes findings from a range of scientific literature, including experimental studies, clinical trials, and biochemical analyses that focus on the role of MAO-B in neurodegeneration. Information was gathered from databases such as PubMed, Scopus, and Web of Science, ensuring a comprehensive overview of recent advancements in MAO-B inhibition strategies. The review reveals several promising MAO-B inhibitors that have demonstrated efficacy in preclinical models, as well as some that have progressed to clinical trials. Compounds such as rasagiline and selegiline have shown neuroprotective effects and benefits in symptom management in patients with Parkinson's disease. Furthermore, the review discusses novel inhibitors that target specific molecular pathways, enhancing the potential for improved therapeutic outcomes. However, several inhibitors also present challenges regarding their selectivity, side effects, and long-term efficacy. Research on MAO-B inhibitors for neurodegenerative diseases is crucial, with ongoing studies aiming for selective, potent molecules with fewer side effects and multimodal therapies.

2025-04-11·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Integrating Circular Polarized Luminescence and Long Persistent Luminescence in Cu₈ Cage‐Like Clusters via Ligand Engineering

Article

作者: Zhan, Wen‐Wen ; Zhou, Jie ; Li, Yan ; Yang, Yang ; Zheng, Hao ; Wu, Guanyi ; Sun, Di ; Zhang, Chengkai

Abstract:

Copper clusters with diverse luminescent properties are of particular interest. In this study, a series of Cu8 clusters with cage‐like structures was synthesized and characterized. By employing a stepwise ligand engineering strategy that progressively introduced circularly polarized luminescence (CPL) and long persistent luminescence (LPL) properties, we successfully synthesized R/S‐Cu8−Cl, the first copper cluster to demonstrate both CPL and LPL. The CPL originates from the chiral metal core induced by the chiral alkynyl ligand, whereas the LPL is attributed to the inherent properties of chlorine‐modified triphenylphosphine, which is retained and modified after ligation. The polymethyl methacrylate (PMMA) film containing Cu8 clusters displays lifetimes of up to 75.18 ms at room temperature and an afterglow exceeding 1.5 s, marking the longest luminescent lifetime recorded for molecular copper‐cluster‐based materials known to date. Additionally, R/S‐Cu8−Cl shows excitation‐dependent luminescence and variations in luminescence when UV light is switched on and off, highlighting its potential for advanced anti‐counterfeiting applications. This work not only presents innovative cage‐like copper cluster structures but also offers new approaches for designing multifunctional clusters.

2025-03-27·JOURNAL OF MEDICINAL CHEMISTRY

Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor

Article

作者: Basile, Lorenzo ; Lambona, Chiara ; Garofalo, Stefano ; Fioravanti, Rossella ; Mai, Antonello ; Massari, Marta ; Noce, Beatrice ; Gottinger, Andrea ; Fiorentino, Francesco ; Binda, Claudia ; Valente, Sergio ; Limatola, Cristina ; Castelôa, Mariana ; Mormino, Alessandro ; Marchese, Sara ; Reis, Joana ; Mattevi, Andrea ; Raucci, Alessia

NADPH oxidases (NOXs) are enzymes dedicated to reactive oxygen species (ROS) production and are implicated in cancer, neuroinflammation, and neurodegenerative diseases. VAS2870 is a covalent inhibitor of mainly NOX2 and NOX5. It alkylates a conserved active-site cysteine, blocking productive substrate binding. To enhance potency and selectivity toward NOXs, we conducted some chemical modifications, leading to the discovery of compound 9a that preferentially inhibits NOX2 with an IC₅₀ of 0.155 μM, and only upon its preactivation. We found that 9a, bearing a pargyline moiety, is also able to selectively inhibit MAOB over MAOA (465-fold) with an IC₅₀ of 0.182 μM, being the first-in-class dual NOX2/MAOB covalent inhibitor. Tested in the BV2 microglia neuroinflammation model, 9a decreased ROS production and downregulated proinflammatory cytokines as iNOS, IL-1β, and IL-6 expression more efficiently than the single target inhibitors (rasagiline for MAOB and VAS2870 for NOXs) but also, more importantly, than their combination.

项与甲磺酸雷沙吉兰相关的新闻（医药）

2025-05-08

·赛柏蓝

上千个药挂网价调整，有的从340降至4.8

作者 | 陈芋责编 | 遥望从340元降至4.8元，大批药品挂网价下调。01价格超1.8倍被标记本月底前完成自查降价近日，陕西公共资源交易中心发布《关于对平台异常挂网价格自查自纠的通知》，剑指高价药。据通知，陕西此次以近一年的“加权平均交易价”为锚点，药品当前挂网价与近1年来加权平均交易价比值大于等于1.8倍的，将在省平台被标红管理。医药企业可登陆平台查看标红的相关产品及当前比值（加权平均交易价的计算时间范围为：2024年5月1日至2025年4月30日）。陕西提出，有标红药品及医用耗材产品的企业应在5月31日前进行自查自纠，并主动将挂网价与加权平均交易价的比值降至1.3倍以下，降价后的产品将在6月初取消红色标识，逾期拒绝整改的异常挂网价格产品，将被上报省医保局，按相关规定统一处理。海南也在本月启动了挂网药品价格调整工作，同样对高价药采取红黄标识，但其触发条件与陕西有所不同。不同于陕西的加权平均交易价，海南以近年药品价格治理中新引入的“75%分位数”作为锚点——高于该值1.8倍不高于3倍的，纳入黄标管理；高于3倍的，纳入红标管理。75%分位数是把药品价格按升序排列后找到的一个临界值，即同组中约有75%的药品价格小于等于该值，其余25%的药品价格大于等于该值。海南此批名单共披露436个挂网价高于75%分位数价格1.8倍的药品（名单见文末附1），其中198个因价格高于3倍被标红，238个被标黄。海南提出，企业应在5月12日17:00前登录子系统将价格调至1.8倍以下，符合条件后取消红黄标管理。02从340元降至4.8元上千个药品挂网价调整不止陕西、海南，5月以来，多省相继公布本省挂网价格治理工作进展，上海发布《部分药品红线价格调整公告》，河南发布《关于尼扎替丁分散片等100个药品下调价格的公示》，湖南发布《关于药品挂网价格调整的公告》，江苏发布《关于调整部分药品挂网价格的通知》等；4月，吉林也公布了其《挂网药品价格自查自纠专项治理结果》。从已公布下调结果的省份来看，各省近期的挂网价格调整涉及大批药品。例如，吉林公布的自查自纠专项治理结果共包括2081个药品，涉及注射用头孢曲松钠、磷酸西格列汀片、非布司他片等品种。吉林两千余个药品整体价格降幅约20%，其中，310个药品价格降幅超过50%，降幅最高的一款产品为利伐沙班片，价格从339.72元/盒调整至4.8元/盒，降幅达到98.6%。对于未参与此次调价的企业，吉林表示可于每月1日-10日通过招采子系统展开降价，未按相关要求及时开展价格联动的企业，采购中心将按照国家医保局《关于建立医药价格和招采信用评价制度的指导意见》相关规定处理。河南发布此批公示名单中包括100个药品（名单及企业、价格等见文末附2），涉及紫杉醇注射液、头孢地尼分散片、注射用更昔洛韦等品种，整体平均降幅约14%，其中，降幅最高超过93%，为一款甲磺酸雷沙吉兰片，价格由287.9元按承诺拟供应价降至18元。两年前，国家医保局启动药品挂网价格治理，后逐步完成四同药品价格治理等工作，到2025年，治理进一步深化。全国医疗保障工作会议上，国家医保局明确2025年的八大重点之一是深化医药价格改革治理，不断规范医药价格秩序——推进挂网药品价格治理，推动形成全国药品挂网价格规则共识，全面建立定点药店医保药品量价比较指数等。在医保局组织逐步建立的全国挂网药品价格一览表下，各地挂网价格信息将被汇总，首涨、高涨幅等异常行为也将被标识，各省对各类不合理的挂网高价的纠正还将持续推进。附1：河南关于尼扎替丁分散片等100个药品下调价格的公示附2：海南436个挂网价高于75%分位数价格1.8倍的药品END内容沟通：郑瑶（13810174402）

一致性评价带量采购

2025-05-07

·赞Med

帕金森病症状波动管理新突破

点击上方“蓝字”关注我们吧！我国是世界上人口最多的国家，据2021年公布的GBD数据，我国帕金森病患者数为507.71万，1几乎占到全球帕金森病患病人数的一半。每一位帕金森病患者可以先后或同时表现有运动症状和非运动症状，但在整个病程中都会出现这两类症状，有时会产生多种非运动症状。2 因此应对帕金森病的运动症状和非运动症状采取全面综合治疗。药物治疗作为首选，且是整个治疗过程中的主要治疗手段。用药的原则以达到有效改善症状、避免或降低不良反应、提高工作能力和生活质量为目标。2中晚期帕金森病，尤其晚期帕金森病的临床表现极其复杂，其中有疾病本身的进展，也有药物副作用或运动并发症的因素参与。运动并发症（和异动症）是中晚期患者常见的症状，也是最棘手的治疗难题。3其中主要包括有两种形式:①疗效减退(wearing-off)或剂末现象(end of dose deterioration):指每次用药的有效作用时间缩短，症状随血药浓度波动而发生波动。②“开-关” 现象(on-off phenomenon):指症状在突然缓解(“开期”)与加重(“关期”)之间波动。3一项中国在运动波动相关的研究提示，接受左旋多巴治疗的中国患者在近1年内有29.0%出现，随着治疗时间的增加，发生率会逐步升高，10年以上人群中的发生率则高达68.3%。4图1 源自参考资料5国际帕金森和运动障碍协会（MDS）最新更新的2025年治疗循证综述显示在治疗帕金森病时，MAO-BI分类中的司来吉兰为证据不足，雷沙吉兰为可能有效，而MAO-BI+离子通道阻滞剂分类中的沙非胺（曾称沙芬酰胺）为有效。5表1 源自参考资料5雷沙吉兰与沙非胺在2025年3月发表的一项沙非胺与雷沙吉兰联合左旋多巴治疗中国帕金森病伴患者的匹配调整间接比较研究中，将沙非胺与雷沙吉兰的中国III期研究数据匹配调整后进行比对显示：6图2 源自参考资料6· 在改善“关期”方面，作为左旋多巴的联合治疗，与雷沙吉兰1mg相比，沙非胺100mg将每日“关期”时间进一步缩短了0.7小时(MD = -0.7,95% CI: -1.40, -0.02, p＜0.05)。· 在改善UPDRS III评分方面，沙非胺也比雷沙吉兰更有效。与雷沙吉兰相比，沙非胺可进一步改善UPDRS III评分2.9分(MD = -2.9, 95% CI: -5.28, -0.52, p＜0.05)。· 在PDQ-39总分、日常生活行为评分、精神健康评分、身体活动评分和屈辱感评分方面，尽管结果无统计学差异，但沙非胺组在数值上均优于雷沙吉兰组，有优于雷沙吉兰的趋势。· 在安全性方面，不良事件发生率(OR = 1.6, 95% CI: 0.83, 3.19)、严重不良事件发生率(OR = 1.1, 95% CI: 0.21, 6.14)和因不良事件停药率(OR = 0.7, 95% CI: 0.14, 3.28)方面均无明显差异。该研究提示了在中国人群中，沙非胺100mg/日在改善运动波动、运动功能、生活质量方面较雷沙吉兰1mg/日疗效更优，且无安全性差异。6表2 源自参考资料6沙非胺即将上市2024年12月沙非胺已在中国获批，随着今年沙非胺即将在中国上市，帕金森病患者将获得新型双重机制疗法的治疗选择。该药物的临床优势体现在的改善、运动症状的控制及非运动症状方面的综合获益，有望为患者提供更优化的疾病管理方案。参考文献[1] Xu T, Dong W, Liu J, et al. Disease burden of Parkinson's disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021. Lancet Reg Health West Pac. 2024;46:101078. Published 2024 May 8.[2] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南（第四版）[J]. 中华神经杂志,2020,53(12):973 -986.[3] 郝峻巍,罗本燕.神经病学(第9版)[M].人民卫生出版社.2024.[4] Wan Y, Yuan C, Hou X,et al. Wearing-off Identification in Parkinson's Disease: The shapd-woq Study. Front Neurol. 2020 Mar 13;11:116.[5] de Bie RMA, Katzenschlager R, Swinnen BEKS, et al. Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Mov Disord. 2025 Mar 8.[6] Tan Y, Wei Q, Xu P et al.Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson's disease patients with a matching adjusted indirect comparison. Sci Rep. 2025 Mar 26;15(1):10502.提示：本材料仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。

临床3期临床结果临床成功

2025-04-22

·PRNewswire

XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight

As a selective monoamine oxidase B (MAO-B) inhibitor, XADAGO offers a unique mechanism of action that complements traditional therapies, potentially improving motor function and reducing "off" time in patients. The increasing prevalence of Parkinson's disease and the growing demand for effective therapies create a substantial market opportunity for XADAGO, particularly in regions with aging populations. LAS VEGAS, April 22, 2025 /PRNewswire/ -- DelveInsight's " XADAGO/EQUFINA Market Size, Forecast, and Market Insight Report" highlights the details around XADAGO/EQUFINA, an inhibitor of monoamine oxidase B (MAO-B) indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of XADAGO/EQUFINA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Newron Pharmaceuticals/Eisai/Meiji Seika Pharma's XADAGO/EQUFINA (safinamide) Overview XADAGO is a monoamine oxidase B (MAO-B) inhibitor used alongside levodopa/carbidopa to help manage "off" episodes in individuals with Parkinson's disease. While its exact mode of action in treating Parkinson's is not fully understood, it is thought to work by inhibiting MAO-B, thereby reducing dopamine breakdown. This leads to increased dopamine levels and enhanced dopaminergic activity in the brain. XADAGO contains the active ingredient safinamide in the form of a mesylate salt and is available in 50 mg and 100 mg film-coated oral tablets. Each tablet provides either 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg of the safinamide base. The medication is marketed as XADAGO in the United States and Europe and under the name EQUFINA in Japan. Learn more about XADAGO/EQUFINA projected market size for Parkinson's disease @ XADAGO/EQUFINA Market Potential Parkinson's disease is a progressive neurological disorder that mainly impairs movement control. It results from the slow degeneration of dopamine-producing neurons in the brain, especially in the substantia nigra, a region crucial for managing voluntary motor function. According to estimates by DelveInsight, there were 2.7 million diagnosed prevalent cases of Parkinson's disease in the 7MM in 2023, with the United States accounting for around 45% of these cases. While a cure for Parkinson's remains elusive, a combination of pharmacological and non-pharmacological therapies is used to manage symptoms. Physical, occupational, and speech therapies form key components of treatment, and surgical procedures may benefit select patients. Additionally, complementary therapies are sometimes employed to help address particular symptoms. Frequently prescribed medications for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A antagonists. These treatments primarily target motor symptoms, which are a major concern for those affected. DelveInsight reports that the Parkinson's disease market in the 7MM was valued at USD 3.2 billion in 2023. The market is expected to grow over the forecast period (2020–2034), fueled by the launch of new therapies, increasing prevalence, better access to healthcare, and rising demand for more advanced and effective treatment options. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of XADAGO/EQUFINA Some of the drugs in the pipeline include Solengepras (Cerevance), Minzasolmin (UCB Biopharma SRL/Novartis), Buntanetap (Annovis Bio), and others. Buntanetap has successfully completed Phase III trials for early-stage Parkinson's disease. Annovis Bio has scheduled a meeting with the FDA in Q1 2025 to determine the development path forward for Buntanetap in the treatment of Parkinson's disease. Buntanetap is also being developed for Alzheimer's disease, Lewy Body Dementia, and other neurodegenerative disorders. In November 2024, Cerevance announced the dosing of the first patient in its pivotal Phase III ARISE trial, evaluating solengepras as a potential adjunctive treatment for Parkinson's disease. Cerevance expects to report topline data in the first half of 2026. In December 2021, UCB partnered with Novartis to globally co-develop and co-commercialize UCB0599, a pioneering alpha-synuclein misfolding inhibitor currently in Phase II clinical trials for Parkinson's disease. To know more about the number of competing drugs in development, visit @ XADAGO/EQUFINA Market Positioning Compared to Other Drugs Key Milestones of XADAGO/EQUFINA In April 2020, Newron Pharmaceutical acknowledged that US WorldMeds, who held the US commercialization rights for the licensed drug, XADAGO, as a sub licensee of Zambon, had entered into a definitive agreement with Supernus Pharmaceuticals under which Supernus would acquire the CNS portfolio of US WorldMeds, including the US rights to XADAGO In November 2019, Eisai announced that it had launched the EQUFINA 50mg tablets for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan. Manufacturing and marketing approval of EQUFINA was obtained in September 2019. In April 2017, Eisai Co., Ltd. and Meiji Seika Pharma announced entering into a license agreement for the commercialization of safinamide (development code: ME2125) to treat Parkinson's disease in Japan and Asia. In March 2017, Newron Pharmaceuticals announced the US FDA approval of XADAGO to treat Parkinson's disease as an add-on therapy to levodopa/carbidopa for patients experiencing "off" episodes. In March 2016, Zambon announced a strategic agreement with US WorldMeds to commercialize Newron's lead compound, XADAGO, to treat Parkinson's disease in the US. In February 2015, XADAGO was approved in the European Union as an add-on therapy to levodopa, alone or in combination with other Parkinson's medications, in mid-late stage PD patients with motor fluctuations. XADAGO/EQUFINA Patent Details XADAGO tablets are currently protected by three XADAGO patents with US patent numbers 8,076,515, 8,278,485, and 8,283,380, which expire between June 2027 and December 2028 and are listed in the FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. The company has a license agreement with Zambon S.p.A., Newron's partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO is under the 5-year FDA exclusivity period that expires on March 21, 2022. In May 2017, Zambon filed a worldwide patent under the patent number WO2017207587A1. The invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles, and a process for preparing them. Discover how XADAGO/EQUFINA is shaping the Parkinson's disease treatment landscape @ XADAGO 50mg XADAGO/EQUFINA Market Dynamics XADAGO, marketed as EQUFINA in some regions (notably in South Korea and Japan), is a once-daily oral selective MAO-B inhibitor used as an add-on treatment for Parkinson's disease patients experiencing "off" episodes while on a stable dose of levodopa. The drug's unique dual mechanism of action—MAO-B inhibition and modulation of glutamate release—offers both dopaminergic and non-dopaminergic effects, positioning it as a differentiated product in the PD adjunctive therapy landscape. This has helped it carve a niche in markets where patients are inadequately controlled by levodopa alone, particularly those in mid-to-late-stage PD. The global market dynamics for XADAGO/EQUFINA are shaped by a mix of competitive intensity, regional adoption trends, and payer dynamics. In the U.S. and Europe, the drug has faced stiff competition from generic MAO-B inhibitors (like selegiline and rasagiline) and newer Parkinson's disease therapies, including COMT inhibitors, dopamine agonists, and extended-release levodopa formulations. Despite this, its favorable safety profile and once-daily dosing have supported its uptake in certain patient segments, especially in Europe. Market penetration has been slower in the U.S. due to both reimbursement hurdles and physician preference for more established adjunctive treatments. In Asia, particularly Japan and South Korea, EQUFINA has demonstrated stronger market performance thanks to focused commercial strategies and a high unmet need for effective "off time" management. Meiji Seika Pharma and Eisai, the regional marketing partners, have successfully leveraged the drug's differentiated profile in clinician education, which has led to growing adoption among neurologists. In Japan, where the aging population is rapidly expanding and Parkinson's prevalence is rising, EQUFINA has benefited from both demographic tailwinds and formulary access. Looking ahead, the market outlook for XADAGO/EQUFINA depends on several strategic levers, including lifecycle management, regional partnerships, and real-world evidence generation. The manufacturer's ability to expand into new geographies, secure favorable reimbursement, and differentiate against both generics and newer entrants will be critical. Moreover, as Parkinson's disease treatment moves toward more personalized approaches, XADAGO/EQUFINA may find sustained relevance in specific subpopulations, particularly those requiring a balance of efficacy and tolerability. Dive deeper to get more insight into XADAGO/EQUFINA's strengths & weaknesses relative to competitors @ XADAGO/EQUFINA Market Drug Report Table of Contents Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准引进/卖出临床2期

100 项与甲磺酸雷沙吉兰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02562	甲磺酸雷沙吉兰	N04BD02	DB01367

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	欧盟	Teva Pharmaceuticals Europe BV	2005-02-21
帕金森病	冰岛	Teva Pharmaceuticals Europe BV	2005-02-21
帕金森病	列支敦士登	Teva Pharmaceuticals Europe BV	2005-02-21
帕金森病	挪威	Teva Pharmaceuticals Europe BV	2005-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
精神运动障碍	临床3期	-	H. Lundbeck A/S	2011-01-01
不宁腿综合征	临床3期	美国	Teva Neuroscience, Inc.	2010-09-01
帕金森病（青年型、早发型）	临床3期	-	Teva Neuroscience, Inc.	1997-07-01
多系统萎缩	临床2期	美国	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	奥地利	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	加拿大	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	法国	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	德国	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	匈牙利	H. Lundbeck A/S	2009-12-01
多系统萎缩	临床2期	以色列	H. Lundbeck A/S	2009-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03727139 (JapicCTI-184181, Pubmed \| Expert Opin Drug Saf)	N/A	帕金森病	961	Rasagiline 1 mg once daily	膚願壓願選衊繭齋夢積(鑰蓋淵淵構構簾鹽襯觸) = 繭淵衊廠餘選齋觸糧餘構醖夢蓋夢齋積鹹齋範 (淵範獵糧壓糧鹹夢鏇膚 )	积极	2024-01-02
NCT02789020 (CTgov)	临床2期	帕金森病	96	functional Magnetic Resonance Imaging+Rasagiline (Rasagiline)	廠構鏇構網繭窪淵廠鬱(鹹觸廠積窪醖積網製淵) = 製鏇夢構壓艱選積觸願餘淵範鬱膚範襯築築壓 (膚鑰簾願艱憲選鹹衊範, 0.01) 更多	-	2023-09-06
				functional Magnetic Resonance Imaging (Placebo)	廠構鏇構網繭窪淵廠鬱(鹹觸廠積窪醖積網製淵) = 齋築選鏇鹹觸遞膚遞觸餘淵範鬱膚範襯築築壓 (膚鑰簾願艱憲選鹹衊範, 0.01) 更多
NCT02359552 (R2, CTgov)	临床2期	阿尔茨海默症	50	Placebo (Placebo)	廠廠淵獵鏇鏇獵製範鹽(鏇製艱鬱鬱衊鑰遞衊簾) = 簾夢襯鑰醖鏇餘願簾構鹽遞遞鬱憲選觸顧膚獵 (淵遞齋廠願簾鬱鏇製遞, 0.030) 更多	-	2020-10-20
				Rasagiline (Rasagiline)	廠廠淵獵鏇鏇獵製範鹽(鏇製艱鬱鬱衊鑰遞衊簾) = 襯壓糧齋夢壓願餘襯鬱鹽遞遞鬱憲選觸顧膚獵 (淵遞齋廠願簾鬱鏇製遞, 0.030) 更多
NCT01786603 (CTgov)	临床2期	肌萎缩侧索硬化	80	Rasagiline (Rasagiline)	憲鹽鬱壓獵壓醖齋選鹹(鑰構鏇獵觸餘鑰鹹衊窪) = 衊憲襯淵顧簾廠窪構觸膚鹽獵願獵廠鹹願遞衊 (網蓋窪壓壓願廠衊願蓋, 積簾鏇壓憲築範構鏇鑰 ~ 積簾餘醖範蓋觸醖願選) 更多	-	2020-01-27
				Placebo (Placebo)	憲鹽鬱壓獵壓醖齋選鹹(鑰構鏇獵觸餘鑰鹹衊窪) = 壓鹽齋襯壓窪繭鏇餘醖膚鹽獵願獵廠鹹願遞衊 (網蓋窪壓壓願廠衊願蓋, 鬱窪製觸憲廠繭廠網齋 ~ 夢築顧窪鹽鹹遞製鏇遞) 更多
BIPARK-I and II (MDS2019)	N/A	帕金森病	-	Opicapone 50mg	簾築觸鹽窪淵鏇獵鑰觸(積鏇簾鬱憲願構選衊網) = 憲醖襯鑰衊網襯築壓蓋蓋鏇蓋艱蓋構範觸齋壓 (積餘艱窪鏇夢廠範鏇艱 ) 更多	-	2019-09-22
NCT02337764 (CTgov)	临床3期	帕金森病	222	TVP-1012	繭醖醖製選齋鑰鹽鏇窪 = 夢範襯鹹鏇餘鹹鑰齋憲繭膚襯獵網醖衊淵淵鹽 (糧壓獵鏇餘壓構繭餘壓, 齋醖鹽餘壓鑰廠齋鹽觸 ~ 範鏇簾衊積鏇鏇蓋憲鹹) 更多	-	2019-04-19
NCT02337725 (Pubmed) 人工标引	临床3期	帕金森病	244	Rasagiline	簾醖淵衊遞鹽範淵餘獵(築襯觸簾淵廠淵鏇簾簾): difference = -6.39 (95% CI, -8.530 ~ -4.250), P-Value = <0.0001 更多	积极	2019-03-01
				Placebo
NCT02337751 (Pubmed \| J Neural Transm (Vienna))	临床3期	帕金森病	210	Placebo	醖鬱壓蓋壓遞膚鑰範餘(顧構鹹襯蓋淵鬱繭夢顧) = 艱遞範積鏇構衊顧鑰衊壓餘憲繭淵窪範膚淵廠 (遞選膚獵齋簾願壓構築 ) 更多	-	2019-03-01
				Rasagiline 1 mg/day	醖鬱壓蓋壓遞膚鑰範餘(顧構鹹襯蓋淵鬱繭夢顧) = 夢艱積鑰積選願蓋鹹鏇壓餘憲繭淵窪範膚淵廠 (遞選膚獵齋簾願壓構築 ) 更多
NCT02337751 (CTgov)	临床3期	帕金森病（青年型、早发型）	198	Placebo+TVP-1012 (Placebo + TVP-1012 Group)	窪鹽築鑰鹽窪憲鏇艱醖 = 蓋選夢憲艱簾夢憲淵夢蓋憲願鏇鹹遞廠壓壓顧 (襯遞製壓齋簾糧簾鑰淵, 遞蓋鬱製選蓋遞鑰積願 ~ 糧艱淵選膚鏇範顧鹽範) 更多	-	2019-02-28
				TVP-1012 (TVP-1012 + TVP-1012 Group)	窪鹽築鑰鹽窪憲鏇艱醖 = 餘夢獵製鏇觸膚襯衊襯蓋憲願鏇鹹遞廠壓壓顧 (襯遞製壓齋簾糧簾鑰淵, 糧窪餘網願齋鹽衊齋艱 ~ 壓鹹鏇廠鹹願選鑰餘衊) 更多
NCT02337738 (CTgov)	临床2/3期	帕金森病	404	Placebo	鹽壓獵構憲獵顧繭顧繭(淵網鑰淵齋鏇觸簾壓遞) = 夢築築憲鏇積夢顧選鏇鬱餘壓範網遞醖鏇蓋蓋 (選壓餘膚艱餘網壓廠鹽, 0.167) 更多	-	2019-02-28